Artificial intelligence and machine learning will drive incredible efficiency and effectiveness in drug development and speed to market.
Our strategic investments in several innovative ML/AI and data science companies will allow our development teams to identify unexpected synergistic drug combinations, repurpose existing drugs, discover novel drug targets, and accelerate opportunities into the clinic. We will use these capabilities to impact our own projects as well as new partnerships. This is one of our key competitive advantages as we reduce the cost and increase the speed with which new medicines get to patients.
Relation Therapeutics and Mila, the Montreal-based AI research institute are collaborating on a new project targeting the development of COVID-19 therapeutics funded by the Bill & Melinda Gates Foundation.